Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are widely used in Mexico to treat respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). These drugs help to relax the muscles around the airways in the lungs, making it easier to breathe.
Customer preferences: Mexican consumers are increasingly preferring bronchodilator drugs that are more effective and have fewer side effects. They are also looking for drugs that are affordable and easily accessible. As a result, many consumers are opting for generic bronchodilator drugs over branded ones.
Trends in the market: The bronchodilator drugs market in Mexico is expected to grow in the coming years due to the increasing prevalence of respiratory diseases in the country. The market is also being driven by the introduction of new drugs that are more effective and have fewer side effects. In addition, the government's efforts to improve healthcare access and affordability are also expected to boost the market.
Local special circumstances: Mexico has a high prevalence of respiratory diseases such as asthma and COPD, which is driving the demand for bronchodilator drugs. The country also has a large population, which makes it an attractive market for pharmaceutical companies. However, the market is also highly competitive, with many local and international players vying for market share.
Underlying macroeconomic factors: Mexico's economy has been growing steadily in recent years, which has led to an increase in disposable income among consumers. This has made healthcare more affordable and accessible, leading to higher demand for bronchodilator drugs. The government's efforts to improve healthcare access and affordability are also expected to boost the market. However, the market is also subject to regulatory risks, as the government has been implementing price controls on drugs to improve affordability for consumers.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
